Table 4.
Variables | Total (%) | Male (%) | Female (%) | p |
---|---|---|---|---|
Sepsis/bacterial infection | 350 | 190 (54.30) | 160 (45.70) | |
Urinary | 88 (25.10) | 40 (11.40) | 48 (13.70) | |
Digestive | 75 (21.50) | 47 (13.40) | 28 (8.10) | |
Pulmonary | 64 (18.30) | 38 (10.90) | 26 (7.40) | .403 |
Unknown origin | 49 (14.00) | 30 (8.60) | 19 (5.40) | |
Cutaneous | 37 (10.60) | 19 (5.40) | 18 (5.20) | |
Meningitis | 18 (5.10) | 5 (1.40) | 13 (3.70) | |
Septicemia | 13 (3.70) | 9 (2.60) | 4 (1.10) | |
Gynecology | 4 (1.10) | 0 (0.00) | 4 (1.10) | |
Endocarditis | 1 (0.30) | 1 (0.30) | 0 (0.00) | |
Chronic otitis | 1 (0.30) | 1 (0.30) | 0 (0.00) | |
Volume depletion | 203 | 112 (55.20) | 91 (44.80) | |
Hemorrhage | 48 (23.70) | 27 (13.30) | 21 (10.40) | |
Gastroenteritis | 47 (23.10) | 26 (12.70) | 21 (10.40) | |
Diabetes mellitus | 44 (21.70) | 21 (10.40) | 23 (11.30) | .701 |
Heart failure | 36 (17.70) | 19 (9.40) | 17 (8.30) | |
Liver cirrhosis | 14 (6.80) | 9 (4.40) | 5 (2.40) | |
Diuretics | 6 (2.90) | 5 (2.40) | 1 (0.50) | |
Burn | 4 (2.00) | 3 (1.50) | 1 (0.50) | |
Intestinal occlusion | 2 (1.00) | 1 (0.50) | 1 (0.50) | |
NSAID | 1 (0.50) | 1 (0.50) | 0 (0.00) | |
Unspecified | 1 (0.50) | 0 (0.50) | 1 (0.00) | |
Obstructive AKI | 22 | 5 (22.70) | 17 (77.30) | |
Pelvic tumor | 18 (81.80) | 5 (22.70) | 13 (59.10) | |
Cervical cancer | 13 (2.10) | 0 (0.00) | 13 (2.10) | |
Prostate cancer | 4 (0.70) | 4 (0.70) | 0 (0.00) | |
BPH | 1 (0.20) | 1 (0.20) | 0 (0.00) | .004 |
Ureters ligation | 2 (9.20) | 0 (0.00) | 2 (9.20) | |
Retroperitoneal ibrosis | 1 (4.50) | 0 (0.00) | 1 (4.50) | |
Renal stones | 1 (4.50) | 0 (0.00) | 1 (4.50) |
NSAID: non-steroidal anti-inflammatory drugs; BPH: benign prostatic hyperplasia.
Bold indicates the significant p values.